



Crescendo Biologics to participate in upcoming investor and partnering conferences

Cambridge, UK, 24 October 2023 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that members of the executive team will be participating at the following events.

- **Bank of America Healthcare Trailblazers Private Company Conference, 25 - 26 October 2023**
- **BIO-Europe, 6 - 8 November 2023**
- **Jefferies London Healthcare Conference, 14 - 16 November 2023**

The team looks forward to discussing the Company's business strategy, technology, discovery platform and development programmes. To connect with the Company at or around these events, please email investors@crescendobiologics.com.

Please refer to the conference websites for further information and any updated schedules.

-Ends-

For more information, please contact:

Crescendo Biologics

Theodora Harold, CEO
+ 44 (0) 12 2349 7140
investors@crescendobiologics.com
media@crescendobiologics.com

ICR Consilium

Mary-Jane Elliott, Suki Virji, David Daley
+ 44 (0) 20 3709 5700
crescendo@consilium-comms.com

About Crescendo Biologics

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment.

The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human V_H domain building blocks (Humabody V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they



deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital and Kreos Capital.

Please visit our website www.crescendobiologics.com and follow us on [LinkedIn](#) and Twitter [@HUMABODY](#) for more information.